Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Now Available at iData Insights Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Summary Global Markets Direct,s Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 , provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development 1
strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124214/metastatic-liver-cancer-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124214/metastatic-liver-cancer-pipeline-review-h2-2015 Table of Contents able of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10 Therapeutics Development 11 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis 12 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 13 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 18
2
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 20 AbbVie Inc. 20 Amarantus Bioscience Holdings, Inc. 21 Astellas Pharma Inc. 22 Avineuro Pharmaceuticals, Inc. 23 Bristol-Myers Squibb Company 24 Eli Lilly and Company 25 FORUM Pharmaceuticals Inc. 26 H. Lundbeck A/S 27 Intra-Cellular Therapies, Inc. 28 Iproteos S.L. 29 Mnemosyne Pharmaceuticals, Inc. 30 Neuralstem, Inc. 31 Pfizer Inc. 32 Saniona AB 33 Siena Biotech S.p.A. 34 SK Biopharmaceuticals Co., Ltd. 35 Sunovion Pharmaceuticals Inc. 36 Takeda Pharmaceutical Company Limited 37 Upsher-Smith Laboratories, Inc. 38 Vanda Pharmaceuticals Inc. 39 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45
3
Assessment by Molecule Type 47 Drug Profiles 49 A-431404 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AN-761 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AQW-051 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ASP-4345 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ASP-5736 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AUT-1 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AUT-6 - Drug Profile 55 4
Product Description 55 Mechanism of Action 55 R&D Progress 55 AUT-9 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AVL-3288 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 AVN-211 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 DSP-3748 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 eltoprazine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 encenicline hydrochloride - Drug Profile 62 Product Description 62 Mechanism of Action 62
5
R&D Progress 62 erteberel - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 IC-041 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 IPR-001 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IPR-088 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 IPR-19 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ITI-214 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 LUAF-64280 - Drug Profile 71 Product Description 71 6
Mechanism of Action 71 R&D Progress 71 NSI-189 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 PF-04958242 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 PNU-120596 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 roflumilast - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SEN-15924 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 SKL-15508 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80
7
SKL-A4R - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules to Agonize NMDA2B for CIAS - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 TAK-058 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 TAK-915 - Drug Profile 88 Product Description 88 8
Mechanism of Action 88 R&D Progress 88 Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates 89 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 101 Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 103 Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 104 Featured News & Press Releases 104 Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimers Disease and Cognitive Impairment in Schizophrenia 104 Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia 104 Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia 105 Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia 106 Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 107 Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110 Read More http://www.idatainsights.com/reports-landing-page.php?id=124214/metastatic-livercancer-pipeline-review-h2-2015 About Us: 9
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
10